Health Disparity Research Award (HDRA)

At the time of proposal submission, must be:

• HDRA-Transitioning Investigator: A mentored investigator within 3 years of having started the first independent faculty position (or equivalent) or with documentation of receipt of such a position; or
• HDRA-Early-Career Investigator: An independent investigator within 6 years of having completed postdoctoral or fellowship training, at the level of Assistant Professor (or equivalent), with less than $300,000 in direct costs in aggregate as a PI or co-PI of a federally or privately funded, non-mentored, peer-reviewed grant; or
• HDRA-Established Investigator: An independent investigator 6 or more years beyond the last postdoctoral fellowship, with access to appropriate facilities

• Funds innovative health disparity-focused projects by investigators at multiple points in their careers
• PI or collaborator(s) should have a connection to, or effectiveness in working with, the affected population or community
• For HDRA-Transitioning Investigator and HDRA-Early-Career Investigator PIs, award provides 50% protected time for research
• Clinical trials are not permitted
• Designated mentor required for HDRA-Transitioning Investigator Awards
• Collaborator with experience in prostate cancer health disparity research required for HDRA-Early-Career Investigator Awards
• Preliminary data are not required

• HDRA-Transitioning Investigator and HDRA-Early-Career Investigator Awards: A maximum of $225,000 for direct costs for up to a 3-year performance period, plus indirect costs as appropriate
• HDRA-Established Investigator Awards: A maximum of $375,000 for direct costs for up to a 3-year performance period, plus indirect costs as appropriate
• Anticipate 8 awards

Health Disparity Training Award

Predoctoral Ph.D. and M.D./Ph.D.: Must be enrolled full-time in an accredited doctoral program and have completed all predissertation requirements by October 1, 2008; or

Postdoctoral Ph.D.: Must have defended doctoral thesis and have 3 years or less of postdoctoral fellowship experience by October 1, 2008; or

Postdoctoral M.D.: Able to devote at least 40% effort and, by August 1, 2008:

• Must be enrolled in an accredited intern training program; or
• Must be enrolled in an accredited residency or fellowship training program with at least 2 years remaining; or
• Must be within 3 years of the last formal training

• Supports training opportunities in prostate cancer disparity for individuals in the early stages of their careers
• PI must have a designated mentor who is an experienced prostate cancer health disparities researcher
• Mentor must demonstrate a connection to, or effectiveness in working with, the affected population or community

• Predoctoral Ph.D. and M.D./Ph.D. Awards: A maximum of $92,500 for direct costs for up to a 3-year performance period
• Postdoctoral Ph.D. Awards: A maximum of $115,000 for direct costs for up to a 2-year performance period
• Postdoctoral M.D. Awards: A maximum of $60,000 for direct costs for a 1-year performance period or $120,000 for direct costs for a 2-year performance period
• Indirect costs will not exceed 8% of direct costs
• Anticipate 6 awards

Clinical Consortium Award

• Independent investigators at or above the level of Assistant Professor (or equivalent) with experience in performing multi-institutional prostate cancer clinical trials
• Investigators currently funded under the Clinical Consortium Award are eligible to apply
• Submissions from investigators at institutions with enhanced access to patients from disproportionately affected populations are encouraged

• Supports the development of a consortium that will facilitate the rapid execution of collaborative Phase II or Phase I/II clinical trials
• One coordinating center and 12 study sites will be selected and will be jointly responsible for proposing, selecting, and conducting trials
• Sites must provide plans for accruing patients from populations disproportionately affected by prostate cancer
• Trials that incorporate clinical validation of novel biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression are strongly encouraged
• The consortium is expected to achieve financial self-sufficiency such that operations can continue after the award ends

• Coordinating Center: A maximum of $4.7M for direct costs for up to a 5-year performance period, plus indirect costs as appropriate
• Study Sites: A maximum of $1M per site for direct costs for up to a 5-year performance period, plus indirect costs as appropriate
• Anticipate 1 coordinating center and 12 study site awards

Clinical Trial Award

All levels of experience

• Supports rapid execution of Phase 0/I, Phase I, Phase I/II, or Phase II clinical trials with the potential to have a significant impact on prostate cancer
• Studies in a broad range of areas may be submitted including, but not limited to, evaluation of novel drugs, biologics, or devices; psychosocial interventions; behavioral, diet, survivorship, and quality of life studies
• Sufficient study material (drug, device, etc.) must be available and ready for clinical trials at the time the award is made
• Clinical trials are expected to be initiated within 6 months of the award date
• Investigational New Drug or Investigational Device Exemption approval must be received by April 30, 2009

• A maximum of $750,000 for direct costs for up to a 3-year performance period, plus indirect costs as appropriate
• Anticipate 3 awards

Laboratory - Clinical Transition: Stage I Award

All levels of experience

• Funds goal- and product-driven preclinical studies of promising lead agents that may revolutionize prostate cancer clinical care
• PI is expected to have identified either one lead agent or a limited number of lead agents for optimization before applying
• Optimization studies must be completed within 12 months of the start date of the award
• Does not support target discovery, drug screening, device development, development of diagnostic biomarkers, studies of conventional therapeutics, or clinical trials
• Preliminary data are required to demonstrate target availability in human prostate cancer tissues and support the relevance of the target for the prevention, detection, or treatment of human prostate cancer

• A maximum of $750,000 for direct costs for up to a 3-year performance period, plus indirect costs as appropriate
• Anticipate 4 awards

Idea Development Award

Independent investigators at or above the level of Assistant Professor (or equivalent)

• Supports innovative, high-impact, high-risk/high-gain approaches to prostate cancer research
• Preliminary data relevant to prostate cancer and the proposed project are encouraged but not required
• Clinical trials are not permitted

• A maximum of $375,000 for direct costs for up to a 3-year performance period, plus indirect costs as appropriate
• Anticipate 55 awards

Synergistic Idea Development Award

Independent investigators at or above the level of Assistant Professor (or equivalent)

• Supports new or existing partnerships between two or three independent investigators to address a central, innovative, high-risk/high-gain, prostate cancer research question
• Proposals must clearly define the synergistic components that will result in significant achievements unattainable through independent efforts
• Preliminary data relevant to prostate cancer and the proposed project are encouraged but not required
• Clinical trials are not permitted

• A maximum of $750,000 for direct costs for up to a 3-year performance period, plus indirect costs as appropriate
• Each partner will be a PI and will receive an individual award
• Anticipate funding 5 proposals, representing 10 to 15 individual awards

New Investigator Award

Independent investigators who, at the time of submission:

• are within 6 years of having completed postdoctoral or fellowship training; and
• hold position of Instructor, Assistant Professor, or equivalent; and
• have received no more than $300,000 in direct costs in aggregate as a PI or co-PI of a federally or privately funded, non-mentored, peer-reviewed grant

• Supports early-career investigators with innovative, high-impact ideas or new technologies relevant to prostate cancer
• Must have a collaborator with experience in prostate cancer research
• Preliminary data are not required
• Clinical trials are not permitted

• A maximum of $225,000 for direct costs for up to a 3-year performance period, plus indirect costs as appropriate
• Anticipate 23 awards

Collaborative Undergraduate Historically Black Colleges and Universities (HBCU) Student Summer Training Program Award

Independent investigators at or above the level of Assistant Professor (or equivalent) with a proven record in prostate cancer research and training

• Supports new or existing summer prostate cancer training programs for undergraduate HBCU students (at least 4 per year) at institutions with ongoing prostate cancer research
• PI's institution must have a record of achievement in prostate cancer research and training

• A maximum of $185,000 for direct costs for up to a 3-year performance period, plus indirect costs as appropriate
• Anticipate 2 awards

Physician Research Training Award

At the time of proposal submission, must be:

• a physician with clinical duties and/or responsibilities in the last year of an accredited medical residency or medical fellowship program; or
• a physician within 3 years of having received his or her appointment as an Instructor or Assistant Professor

• Supports training of physicians with clinical duties for careers in prostate cancer research
• Requires a mentor with an established research program in prostate cancer
• Provides 40% protection of the PI's time for research

• A maximum of $130,000 per year for direct costs for a minimum performance period of 3 years and a maximum performance period of 5 years, plus indirect costs not to exceed 8% of direct costs
• Anticipate 8 awards

Prostate Cancer Training Award

Predoctoral Ph.D. and M.D./Ph.D.: Must be enrolled full-time in an accredited doctoral program and have completed all predissertation requirements; by October 1, 2008; or

Postdoctoral Ph.D.: Must have defended doctoral thesis and have 3 years or less of postdoctoral fellowship experience by October 1, 2008; or

Postdoctoral M.D.: Able to devote at least 40% effort and, by August 1, 2008:

• Must be enrolled in an accredited intern training program; or
• Must be enrolled in an accredited residency or fellowship training program with at least 2 years remaining; or
• Must be within 3 years of the last formal training

• Provides prostate cancer research training opportunities to individuals in the early stages of their careers
• PI must have a designated mentor

• Predoctoral Ph.D. and M.D./Ph.D. Awards: A maximum of $92,500 for direct costs for up to a 3-year performance period
• Postdoctoral Ph.D. Awards: A maximum of $115,000 for direct costs for up to a 2-year performance period
• Postdoctoral M.D. Awards: A maximum of $60,000 for direct costs for a 1-year performance period or $120,000 for direct costs for a 2-year performance period
• Indirect costs will not exceed 8% of direct costs
• Anticipate 31 awards